TY - JOUR
T1 - Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) initially diagnosed as ALG6-CDG
T2 - Functional evidence for benignity of the ALG6 c.391T>C (p.Tyr131His) variant and further expanding the BBSOAS phenotype
AU - Starosta, Rodrigo Tzovenos
AU - Tarnowski, Jessica
AU - Vairo, Filippo Pinto e.
AU - Raymond, Kimiyo
AU - Preston, Graeme
AU - Morava, Eva
N1 - Funding Information:
This work was supported by the Programa Institucional de Internacionalização of the Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior (PRINT/CAPES, Brazil) and funded by the grant titled Frontiers in Congenital Disorders of Glycosylation ( 1U54NS115198-01 ) from the National Institute of Neurological Diseases and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) , and the Rare Disorders Clinical Research Network (RDCRN) , at the National Institute of Health .
Funding Information:
This work was supported by the Programa Institucional de Internacionaliza??o of the Coordenadoria de Aperfei?oamento de Pessoal de N?vel Superior (PRINT/CAPES, Brazil) and funded by the grant titled Frontiers in Congenital Disorders of Glycosylation (1U54NS115198-01) from the National Institute of Neurological Diseases and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS), and the Rare Disorders Clinical Research Network (RDCRN), at the National Institute of Health.
Publisher Copyright:
© 2020 Elsevier Masson SAS
PY - 2020/7
Y1 - 2020/7
N2 - Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is a recently described autosomal dominant syndrome of developmental delay, cortical vision loss with optic nerve atrophy, epilepsy, and autism spectrum disorder. Due to its many overlapping features with congenital disorders of glycosylation (CDG), the differential diagnosis between these disorders may be difficult and relies on molecular genetic testing. We report on a 31-year-old female initially diagnosed with ALG6-CDG based on glycosylation abnormalities on transferrin isoelectrofocusing and targeted genetic testing, and later diagnosed with BBSOAS by whole-exome sequencing (WES). Functional studies on cultured fibroblasts including Western blotting and RT-qPCR, as well as mass spectrometry of glycosylated transferrin and MALDI-TOF glycan analysis in serum, demonstrated normal glycosylation in this patient. In this report, we extend the phenotype of BBSOAS with ataxia and protein-losing enteropathy. This case is illustrative of the utility of whole exome sequencing in the diagnostic odyssey, and the potential pitfalls of relying on focused genetic testing results for diagnosis of conditions with complex overlapping phenotypes.
AB - Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is a recently described autosomal dominant syndrome of developmental delay, cortical vision loss with optic nerve atrophy, epilepsy, and autism spectrum disorder. Due to its many overlapping features with congenital disorders of glycosylation (CDG), the differential diagnosis between these disorders may be difficult and relies on molecular genetic testing. We report on a 31-year-old female initially diagnosed with ALG6-CDG based on glycosylation abnormalities on transferrin isoelectrofocusing and targeted genetic testing, and later diagnosed with BBSOAS by whole-exome sequencing (WES). Functional studies on cultured fibroblasts including Western blotting and RT-qPCR, as well as mass spectrometry of glycosylated transferrin and MALDI-TOF glycan analysis in serum, demonstrated normal glycosylation in this patient. In this report, we extend the phenotype of BBSOAS with ataxia and protein-losing enteropathy. This case is illustrative of the utility of whole exome sequencing in the diagnostic odyssey, and the potential pitfalls of relying on focused genetic testing results for diagnosis of conditions with complex overlapping phenotypes.
KW - Autism spectrum disease
KW - CDG
KW - Protein-losing enteropathy
KW - Seizure
KW - Transient ataxia
KW - Visual loss
UR - http://www.scopus.com/inward/record.url?scp=85085085110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085085110&partnerID=8YFLogxK
U2 - 10.1016/j.ejmg.2020.103941
DO - 10.1016/j.ejmg.2020.103941
M3 - Article
C2 - 32407885
AN - SCOPUS:85085085110
SN - 1769-7212
VL - 63
JO - European Journal of Medical Genetics
JF - European Journal of Medical Genetics
IS - 7
M1 - 103941
ER -